KIG
SUPN icon

Kowal Investment Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Kowal Investment Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed – – 833
2021
Q3 		$0 Buy
+1
New +$27 ﹤0.01% 1010

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Kowal Investment Group's SUPN Position: Q4 2021 in Review

Kowal Investment Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 1 share.

Kowal Investment Group first reported a position in SUPN in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Kowal Investment Group reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kowal Investment Group sold 1 Supernus Pharmaceuticals share in Q4 2021.
  • Kowal Investment Group first reported a position in Supernus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kowal Investment Group's Supernus Pharmaceuticals position peaked at $0 in Q3 2021.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.